Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications.

Caini, Saverio; Bellerba, Federica; Corso, Federica; Díaz-Basabe, Angélica; Natoli, Gioacchino; Paget, John; Facciotti, Federica; De Angelis, Simone Pietro; Raimondi, Sara; Palli, Domenico; Mazzarella, Luca; Pelicci, Pier Giuseppe; Vineis, Paolo; Gandini, Sara

Caini, Saverio; Bellerba, Federica; Corso, Federica; Díaz-Basabe, Angélica; Natoli, Gioacchino; Paget, John; Facciotti, Federica; De Angelis, Simone Pietro; Raimondi, Sara; Palli, Domenico; Mazzarella, Luca; Pelicci, Pier Giuseppe; Vineis, Paolo; Gandini, Sara.

Caini S; Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Bellerba F; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Corso F; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Díaz-Basabe A; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Natoli G; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Paget J; Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.
Facciotti F; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
De Angelis SP; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Raimondi S; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Palli D; Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Mazzarella L; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Pelicci PG; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Vineis P; Department of Hematology and Oncology, University of Milan, Milan, Italy.
Gandini S; MRC Centre for Environment and Health, School of Public Health, Imperial College, London, United Kingdom.

Euro Surveill ; 25(23)2020 06.

Article Dans Anglais | MEDLINE | ID: covidwho-2313322

ABSTRACT

ABSTRACT

We reviewed the diagnostic accuracy of SARS-CoV-2 serological tests. Random-effects models yielded a summary sensitivity of 82% for IgM, and 85% for IgG and total antibodies. For specificity, the pooled estimate were 98% for IgM and 99% for IgG and total antibodies. In populations with ≤ 5% of seroconverted individuals, unless the assays have perfect (i.e. 100%) specificity, the positive predictive value would be ≤ 88%. Serological tests should be used for prevalence surveys only in hard-hit areas.

Sujets)
Mots clés

SARS-CoV-2; meta-analysis; predictive values; sensitivity; serological tests; specificity; systematic review

Texte intégral

Imprimer

XML

PubMed Links

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Pneumopathie virale / Tests sérologiques / Infections à coronavirus / Coronavirus / Techniques de laboratoire clinique / Infections à Coronaviridae / Syndrome respiratoire aigu sévère / Anticorps antiviraux Type d'étude: Étude diagnostique / Étude observationnelle / Étude pronostique / Essai contrôlé randomisé / Révision Limites du sujet: Humains langue: Anglais Thème du journal: Maladies transmissibles Année: 2020 Type de document: Article Pays d'affiliation: 1560-7917.ES.2020.25.23.2000980

Documents relatifs à ce sujet

MEDLINE

LILACS

LIS

Texte intégral

Imprimer

XML

PubMed Links